Previous close | 24.36 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 1,001 |
Market cap | N/A |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.33 |
Earnings date | 31 Oct 2023 - 06 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN DIEGO, September 19, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia.
SAN DIEGO, August 30, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
If you are looking for some high-octane growth stocks to add to your portfolio, you might want to follow in the footsteps of some of the most successful investors in the biotech sector. Baker Bros. Advisors, a hedge fund founded by billionaire brothers Julian and Felix Baker, has a stellar track record of picking winners in the healthcare space. Two of the fund's top holdings are Acadia Pharmaceuticals (NASDAQ: ACAD) and Roivant Sciences (NASDAQ: ROIV), both of which have delivered impressive returns in the past year.